1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence
Article first published online: 19 AUG 2005
DOI: 10.1111/j.1471-0528.1990.tb01824.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 97, Issue 5, pages 393–396, May 1990
Additional Information
How to Cite
FEDELE, L., VERCELLINI, P., BIANCHI, S., BRIOSCHI, D. and DORTA, M. (1990), Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. BJOG: An International Journal of Obstetrics & Gynaecology, 97: 393–396. doi: 10.1111/j.1471-0528.1990.tb01824.x
Publication History
- Issue published online: 19 AUG 2005
- Article first published online: 19 AUG 2005
- Received 30 August 1989; Accepted 6 December 1989
- Abstract
- References
- Cited By
Summary. Twenty-four women with symptomatic multiple uterine myomas were allocated randomly to treatment with buserelin, 1200μg/day intranasally, for 3 months followed by myomectomy (n = 8) or to immediate myomectomy (n = 16). Pre-operative treatment with buserelin reduced the mean uterine volume from 432 (SD 165) to 242 (SD 82) ml (P < 0.01) but intra-operative blood loss and postoperative morbidity were not significantly less in this group. Six months after operation, pelvic examination was normal in all the patients. However, ultrasonography with transvaginal probe demonstrated the presence of myomas of < 1.5 cm in five women (63%) treated pre-operatively with the analogue and in two women (13%) who underwent immediate surgery (P < 0.05). Induction of a period of hypo-oestrogenism before myomectomy seems to favour short-term recurrence of uterine myomas, limiting the efficacy of surgery.